Because taking a closer look.... 1). He could have pocketed the all money, but didn’t. 2). He could have sold when the share price was, and is in the future, higher. 3). It could be argued that shorts were quick to attack on half due diligence, and then ask why they didn’t get all the details, instead of collecting all the facts prior to making any claims, which prompts such questions. 4). Nader and Kelly sold together, not just Nader alone. Additionally, why would they wait till now to sell? Because the Samsung payment was due. I believe he waited to make that payment until the very end, because a deal or other opportunity could have come up before that would have made it unnecessary. 5). Why would Nader wait until now to supposedly “make profit” and bail, when the company is on the verge of clinical data... data that is supported by ever increasing demand from physicians and cancer patients all the way over in the U.K.? My position is that Nader, as well as plenty of other longs, understand that Leronlimab has demonstrated itself to be an industry disrupting molecule... and NP isn’t about to sell it cheap and leave the shareholders the bag.
I don’t think for one minute that anyone serious about this molecule thinks that Nader is going to “take profit” at these levels knowing what is coming. That alone defies logic to me.
News 
Market Data 
Discover 
